Elections for the Management Advisory Committee (MAC) close on 12th May at the ALTG Members’ Meeting in Melbourne – we are seeking a MAC Secretary and representatives for Allied Health/Nursing, Medical Oncology and Palliative Care. Contact firstname.lastname@example.org for more information.
The first patient has been enrolled into NIVORAD– congratulations to the team at Royal Brisbane and Women’s Hospital – pictured, from L to R: Brett Hughes (PI), Erin Purdon (CT Coordinator), Rob McDowall (Radiation Therapist Consultant – Planning) and Philip Chan (Radiation Oncology Consultant)!
NIVORAD (ALTG 14/002) is a phase 2 placebo-controlled randomised study of nivolumab ± radiotherapy in the treatment of advanced NSCLC and will open at 25 sites in total; site activation is ongoing. This is a valuable opportunity for patients with advanced NSCLC to have access to nivolumab. See our Trials pages for more details.
With successful completion of the safety run-in period, full recruitment to DREAM (ALTG 15/004) has also commenced and is progressing rapidly, with 15/31 patients enrolled in Stage 1. Site activation is ongoing for the 14 sites that will ultimately be open. DREAM is an opportunity for patients with mesothelioma to receive immunotherapy combined with first-line chemotherapy. See our Trials pages for more details.
NIVORAD and DREAM are part of the AUTO-CHECK study, which has been awarded more than $500,000 through Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS). The Genomic Cancer Clinical Trial Initiative (GCCTI) worked with several cooperative oncology groups and the CI, Matthew Cook, to develop and submit the successful application for the AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors.
In other trial news:
- Recruitment to BR.31 (ALTG 14/001; phase 3 placebo controlled randomised study of adjuvant durvalumab in completely resected NSCLC) continues to progress. It is critical for this study that all patients who are being treated surgically are considered for eligibility. This can be best done through the MDT with the support of the lung cancer care coordinator, if available at your site.
- OSCILLATE (ALTG 16/005; alternating osimertinib and gefitinib in patients with EGFR T790M positive NSCLC) is moving rapidly towards opening for recruitment, with the study submitted for central ethics review in March and site selection currently underway. FPI is planned for Q3 2017.